Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

This study tests a new treatment called PRG-2302 — a type of engineered immune cell therapy — for adults with B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer, that has come back or stopped responding to standard treatments. **You may be eligible if...** - You are between 18 and 70 years old - You have confirmed B-cell ALL that has relapsed (come back) or is refractory (did not respond to treatment) - Your bone marrow or blood shows the cancer cells are still present - Your heart, kidneys, and liver are functioning adequately - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have active uncontrolled infection - You have other serious conditions affecting your organ function - You have certain other blood cancers in addition to B-ALL - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.